“Niagen continues to intrigue the scientific community with its potential to support and maintain cellular function across conditions and organ systems,” says
The latest research from CERP includes a recent publication in Biochemical Pharmacology, which found that nicotinamide riboside was unique in its ability in vitro to reduce inflammation in endothelial cells from mice. This study builds on existing clinical and preclinical NR research in the area of cardiovascular health.
Another small human pilot study supported by CERP revealed that NR, in combination with other clinically validated nutrients, improved biomarkers of liver function in healthy subjects. These markers, the investigators surmised, may be important in non-alcoholic fatty liver disease (NAFLD). This research paves the way for additional research and replication in NAFLD patients.
In a third CERP study, NR was found to restore a “younger” circadian rhythm to older mice. Following NR supplementation, older mice re-established cellular function reflective of younger mice, and even displayed a “physically active period” that they had lost with age.
NR was also shown to hold potential for maintaining fertility in spite of aging. In a study of older mice, boosting levels of NAD+ with NR was found to increase the number of ovarian follicles, ovulatory potential and live birth rate.
Another study found that in a mouse model of the rare mitochondrial disease “Gulf War Illness” (GWI), NR resolved fatigue and improved mitochondrial function. NR demonstrated anti-inflammatory effects in mice, consistent with the reduction observed in endothelial cell inflammation cited in an aforementioned study.
The positive findings in mice in these preclinical studies are inspiring further clinical research to explore the full potential of Niagen.
Since Dr. Charles Brenner’s groundbreaking discovery of NR as an effective NAD+-booster in 2004,
For additional information on the science supporting Niagen visit www.chromadex.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to results of the NIAGEN® studies, their significance and whether the studies illustrate the potential of NIAGEN® in bolstering cellular health to counteract or reduce progression of numerous degenerative conditions. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about
ChromaDex Media Contact:
310-388-6706 ext. 689
ChromaDex Investor Relations Contact:
949-419-0288 ext. 127